Lyft Volunteers to Transport Alzheimer’s Patients to and from Clinical Trial Sites

Lyft Volunteers to Transport Alzheimer’s Patients to and from Clinical Trial Sites
The transportation service Lyft is teaming up with the Global Alzheimer’s Platform Foundation to help those who are participating in an Alzheimer's trial get to and from U.S. and Canadian research sites. Under the agreement, Lyft will provide transportation for those taking part in Eli Lilly's Phase 2 TRAILBLAZER-ALZ (NCT03367403) trial and their caregivers. The company hopes to recruit up to 375 participants. Lyft is already helping trial participants get to some trial sites, and will add other sites later. The foundation had previously identified lack of transportation options as a significant barrier to Alzheimer’s trial participation. Because some participants do not have convenient or affordable ways to get to and from research facilities, they often stop participating. This not only hurts results but can also jeopardize a trial's completion. TRAILBLAZER-ALZ is evaluating the safety and effectiveness of LY3002813, alone and in combination with LY3202626, as a treatment for early Alzheimer's disease. LY3002813 is a monoclonal antibody, while LY3202626 is a small-molecule inhibitor. Both recognize and target amyloid plaque in the brain. Lyft will transport patients to and from 15 trial sites in the foundation’s GAP-Net, a group of 63 top academic and private Alzheimer’s research sites in North America. These include Axiom Clinical Research in Tampa, Florida; Banner Alzheimer’s Institute in Phoenix; 
Subscribe or to access all post and page content.